(Reuters) - Swiss drug maker Roche Holding AG plans to acquire a majority stake in U.S.-based molecular and genomic analysis firm Foundation Medicine Inc by buying a combination of outstanding and newly issued shares, the companies said on Monday.
Roche said it will tender for around 15.6 million Foundation shares at $50 a share, worth up to about $780 million, a premium of 109 percent to their Friday closing price. Roche will also invest $250 million in Foundation by acquiring 5 million newly issued shares at $50 per share.
22:33 Allergan to pay $15 million over failing to disclose merger talks16
21:40 HP Enterprise to buy cloud software company SimpliVity16
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
13:16 Wells Fargo earnings: 96 cents per share, vs. expected EPS of $121